Company profile for Healis Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Healis Therapeutics is developing a new class of neuromuscular therapeutics in psychiatry. Healis Co-Founder and CEO Dr. Eric Finzi first made headlines in 2006 when he published the first trial showing efficacy of botulinum toxin.Healis Therapeutics seeks to accelerate the development of botulinum toxin as a potential psychiatric treatment option for depression. Over 19 million Americans suffer from depression, with an estima...
Healis Therapeutics is developing a new class of neuromuscular therapeutics in psychiatry. Healis Co-Founder and CEO Dr. Eric Finzi first made headlines in 2006 when he published the first trial showing efficacy of botulinum toxin.Healis Therapeutics seeks to accelerate the development of botulinum toxin as a potential psychiatric treatment option for depression. Over 19 million Americans suffer from depression, with an estimated 280 million cases worldwide, according to the World Health Organization (WHO). By targeting different neuromuscular pathways than current treatments,

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1 Dock 72 Wy, Brooklyn, NY 11205
Telephone
Telephone
808 726 1720
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2024/03/26/2852293/0/en/Healis-Therapeutics-announces-collaboration-with-Massachusetts-General-Hospital-MGH-and-affiliates-of-Harvard-Medical-School-to-advance-clinical-stage-neuroscience-research.html

GLOBENEWSWIRE
26 Mar 2024

https://www.globenewswire.com//news-release/2024/02/27/2835923/0/en/Healis-Therapeutics-asset-CKDB-501A-shares-Phase-III-topline-results-for-glabellar-injections-from-CKD-Bio-in-South-Korea.html

GLOBENEWSWIRE
27 Feb 2024

https://www.globenewswire.com//news-release/2024/02/12/2827470/0/en/Healis-selected-to-present-at-key-biotechnology-and-neuroscience-investor-conferences-in-Amsterdam-New-York-and-San-Diego.html

GLOBENEWSWIRE
12 Feb 2024

https://www.globenewswire.com//news-release/2024/01/02/2802618/0/en/Healis-Therapeutics-Announces-Supply-Agreement-with-CKD-Bio-to-develop-CKDB-501-for-neuropsychiatric-indications.html

GLOBENEWSWIRE
02 Jan 2024

https://www.globenewswire.com/news-release/2023/12/05/2790838/0/en/Healis-Therapeutics-selected-to-speak-on-opening-day-of-2024-Biotech-Showcase-in-San-Francisco.html

GLOBENEWSWIRE
05 Dec 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty